The estimated Net Worth of David D. Meek is at least 858 千$ dollars as of 13 June 2024. Mr. Meek owns over 2,229 units of uniQure N.V stock worth over 110,778$ and over the last 6 years he sold QURE stock worth over 457,397$. In addition, he makes 290,144$ as Non-Executive Independent Director at uniQure N.V.
Sign up
Mr. Meek QURE stock SEC Form 4 insiders trading
David has made over 8 trades of the uniQure N.V stock since 2020, according to the Form 4 filled with the SEC. Most recently he sold 2,229 units of QURE stock worth 11,412$ on 13 June 2024.
The largest trade he's ever made was selling 4,616 units of uniQure N.V stock on 19 December 2022 worth over 186,533$. On average, David trades about 538 units every 59 days since 2018. As of 13 June 2024 he still owns at least 20,252 units of uniQure N.V stock.
You can see the complete history of Mr. Meek stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
David Meek biography
David Meek serves as Non-Executive Independent Director of the Company. Mr. Meek was appointed President & CEO of FerGene, a gene therapy biotech focused on cancer. From July 2016 to December 2020, Mr. Meek was CEO and a member of the Board of Ipsen. Prior to joining Ipsen, he was Executive Vice-President and President of the oncology division of Baxalta. He spent 2 years as CCO of Endocyte. Mr. Meek also spent 8 years at Novartis as a global franchise head, CEO of Novartis Canada, and region head of oncology for northern, central and Eastern Europe. He also spent 14 years at Johnson & Johnson and Janssen Pharmaceutica, where he held a variety of senior U.S. sales and marketing positions. Mr. Meek holds a B.A. from the University of Cincinnati.
What is the salary of David Meek?
As the Non-Executive Independent Director of uniQure N.V, the total compensation of David Meek at uniQure N.V is 290,144$. There are 8 executives at uniQure N.V getting paid more, with Matthew Kapusta having the highest compensation of 4,719,960$.
How old is David Meek?
David Meek is 56, he's been the Non-Executive Independent Director of uniQure N.V since . There are 6 older and 9 younger executives at uniQure N.V. The oldest executive at uniQure N.V. is Jack Kaye, 76, who is the Non-Executive Independent Director.
What's David Meek's mailing address?
David's mailing address filed with the SEC is C/O UNIQURE N.V., PAASHEUVELWEG 25A, AMSTERDAM, P7, 11058BP.
Insiders trading at uniQure N.V
Over the last 8 years, insiders at uniQure N.V have traded over 35,572,573$ worth of uniQure N.V stock. The most active insiders traders include Deventer Sander Van、Paula Soteropoulos、William Lewis. On average, uniQure N.V executives and independent directors trade stock every 14 days with the average trade being worth of 37,634$. The most recent stock trade was executed by Walid Abi Saab on 26 June 2024, trading 1,447 units of QURE stock currently worth 6,309$.
What does uniQure N.V do?
uniqure is delivering on the promise of gene therapy - single treatments with potentially curative results. we are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary and partnered gene therapies to treat patients with severe genetic diseases.
What does uniQure N.V's logo look like?
Complete history of Mr. Meek stock trades at Mirati Therapeutics Inc、uniQure N.V、Entasis Therapeutics Inc、Fusion Pharmaceuticals、Cullinan Oncology
uniQure N.V executives and stock owners
uniQure N.V executives and other stock owners filed with the SEC include:
-
Matthew Kapusta,
Chief Executive Officer, Chief Financial Officer, Executive Director -
Robert Gut,
Executive Director -
Alexander Kuta,
Executive Vice President, Operations -
Maria Cantor,
Senior Vice President, Investor Relations and Communications -
Matthew Craig Kapusta,
CEO & Exec. Director -
Dr. Alexander E. Kuta Ph.D.,
Exec. VP of Quality & Regulatory -
Dr. Ricardo Dolmetsch Ph.D.,
Pres of R&D -
Christian Klemt,
CFO, Principal Financial Officer & GM of Amsterdam Site -
David Meek,
Non-Executive Independent Director -
Philip Astley-Sparke,
Independent Non-Executive Chairman of the Board -
Jack Kaye,
Non-Executive Independent Director -
Jeremy Springhorn,
Non-Executive Independent Director -
Madhavan Balachandran,
Non-Executive Independent Director -
Paula Soteropoulos,
Non-Executive Independent Director -
Leonard Post,
Director -
Ricardo Dolmetsch,
President, Research and Development -
Erin Boyer,
Chief People & Culture Office -
Richard Porter Ph.D.,
SVP of R&D and GM of Corlieve -
Dr. Tamara Tugal Ph.D., MBA,
Bus. Devel. Director -
Maria E. Cantor,
Chief Communications Officer -
David Cerveny,
Chief Legal Officer, Gen. Counsel & Sec. -
Pierre Caloz,
Chief Operating Officer -
Prof. Hugo Katus,
Chairman of Scientific Advisory Board and Managing Director of UniQure-Germany -
Rachelle Suzanne Jacques,
Director -
Christian Meyer,
Chief Medical Officer -
Harald Petry,
Chief Scientific Officer -
Maiken Keson Brookes,
General Counsel -
Jonathan Garen,
Chief Business Officer -
David Schaffer,
Director -
Paul E Firuta,
Chief Commercial Officer -
William Lewis,
Director -
Steven Zelenkofske,
Chief Medical Officer -
Deventer Sander Van,
EVP, Research & Product Dev. -
Scott T. Mc Millan,
Chief Operating Officer -
Pierre Caloz,
Chief Operating Officer -
Christian Klemt,
Chief Financial Officer -
Jeannette Potts,
Chief Legal Officer -
Walid Abi Saab,
Chief Medical Officer